Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2])

BACKGROUND: Depression is a common psychiatric disorder and a leading cause of disability worldwide. Conventional monoaminergic antidepressants have limited efficacy and take weeks to exert a therapeutic effect. Single infusions of subanaesthetic doses of ketamine exhibit rapid antidepressant action...

Descripción completa

Detalles Bibliográficos
Autores principales: Jelovac, Ana, McCaffrey, Cathal, Terao, Masashi, Shanahan, Enda, Mohamed, Enas, Whooley, Emma, McDonagh, Kelly, McDonogh, Sarah, Igoe, Anna, Loughran, Orlaith, Shackleton, Ellie, O’Neill, Ciaran, McLoughlin, Declan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655414/
https://www.ncbi.nlm.nih.gov/pubmed/37974160
http://dx.doi.org/10.1186/s12888-023-05365-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655414/
https://www.ncbi.nlm.nih.gov/pubmed/37974160
http://dx.doi.org/10.1186/s12888-023-05365-9

Ejemplares similares